164 related articles for article (PubMed ID: 21039410)
1. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.
Booken N; Heck M; Nicolay JP; Klemke CD; Goerdt S; Utikal J
Br J Dermatol; 2011 Mar; 164(3):665-7. PubMed ID: 21039410
[No Abstract] [Full Text] [Related]
2. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
Maroñas-Jiménez L; Estrach T; Gallardo F; Pérez A; Andrés Borja H; Servitje O; Pérez Gala S; Linares Barrio M; Jiménez Gallo D; Sanz-Bueno J; Lora D; Monsálvez V; Ortiz-Romero PL
Br J Dermatol; 2018 Apr; 178(4):e273-e274. PubMed ID: 29150837
[No Abstract] [Full Text] [Related]
3. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.
Borja-Consigliere HA; López-Pestaña A; Vidal-Manceñido MJ; Tuneu-Valls A
Actas Dermosifiliogr; 2014 Sep; 105(7):716-8. PubMed ID: 24139470
[No Abstract] [Full Text] [Related]
4. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
5. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
Muñoz M; Parrilla J; Rosso M; Coveñas R
Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
[No Abstract] [Full Text] [Related]
6. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
7. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.
Meyer N; Paul C; Misery L
Acta Derm Venereol; 2010; 90(1):12-7. PubMed ID: 20107719
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.
Torres T; Fernandes I; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Jan; 66(1):e14-5. PubMed ID: 22177649
[No Abstract] [Full Text] [Related]
9. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
10. Topical aprepitant in clinical and experimental pruritus.
Wallengren J
Arch Dermatol; 2012 Aug; 148(8):957-9. PubMed ID: 22911202
[No Abstract] [Full Text] [Related]
11. Aprepitant as an antipruritic agent?
Duval A; Dubertret L
N Engl J Med; 2009 Oct; 361(14):1415-6. PubMed ID: 19797294
[No Abstract] [Full Text] [Related]
12. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
13. Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Serrano L; Martinez-Escala ME; Zhou XA; Guitart J
Dermatol Clin; 2018 Jul; 36(3):245-258. PubMed ID: 29929596
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant for erlotinib-induced pruritus.
Vincenzi B; Tonini G; Santini D
N Engl J Med; 2010 Jul; 363(4):397-8. PubMed ID: 20660413
[No Abstract] [Full Text] [Related]
15. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
16. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.
Makhlough A; Ala S; Haj-Heydari Z; Kashi Z; Bari A
Iran J Kidney Dis; 2010 Apr; 4(2):137-40. PubMed ID: 20404425
[TBL] [Abstract][Full Text] [Related]
17. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of pruritus.
Ständer S; Weisshaar E
Expert Opin Emerg Drugs; 2012 Sep; 17(3):335-45. PubMed ID: 22870909
[TBL] [Abstract][Full Text] [Related]
20. What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.
Biazus Soares G; Guitart J; Yosipovitch G
Am J Clin Dermatol; 2024 Jan; 25(1):67-77. PubMed ID: 37971624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
